Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

New Orodispersible Mini Tablets of Enalapril Maleate by Direct Compression for Pediatric Patients

Author(s): Claudia A. Ortega, Laura S. Favier*, Valeria A. Cianchino and Diego A. Cifuente

Volume 17, Issue 6, 2020

Page: [505 - 510] Pages: 6

DOI: 10.2174/1567201817666200508093442

Price: $65

Abstract

Background: In many countries, hypertension in the pediatric population is considered a serious risk of mortality and morbidity. In this respect, it is central to design and develop new pharmaceutical forms for pediatric patients with hypertension. The development of Orodispersible Mini-Tablets (ODMTs) for pediatric use has gained importance in recent years. Therefore, regulations for developing suitable and palatable dosage forms for pediatric patients have been established by WHO authorities.

Objective: This study aimed to design and develop orodispersible mini tablets of enalapril maleate (EnM ODMTs) for pediatric use.

Methods: Five pharmaceutical formulations (A, B, C, D and E, shown in Table 1) were designed. The effects of different co-processed excipients and active pharmaceutical ingredients at different doses were studied. Lactose co-processed excipients selected were the following: Tablettose® 80, Microce- Lac® 100 and StarLac®. The micromeritic properties for all the physical mixtures were examined. The mini tablets were obtained by direct compression. Quality control parameters were determined in accordance with US Pharmacopeia.

Results: Three OMDTs with StarLac® showed good results of hardness, flow ability and fast disintegration. The formulation with 0.1 mg of enalapril maleate presented the best results for the official parameters of hardness (4.0 kp), friability (< 1%), disintegration time (28 s), drug content uniformity (103.6 %), and wetting time (23 s).

Conclusion: The three OMDTs with StarLac® showed good quality parameters, according to official requirements. Formulation A exhibited the best wetting time, complying with the dose recommended for pediatric patients. This formulation could be considered eligible for being manufactured at industrial scale.

Keywords: Enalapril maleate, Orodispersible mini tablets, Pediatric form, Co-processed excipients, Hypertension, Direct compression.

« Previous Next »
Graphical Abstract

[1]
Rao, G. Diagnosis, epidemiology and management of hypertension in children. Pediatrics, 2016, 138(2), 1-13.
[http://dx.doi.org/10.1542/peds.2015-3616] [PMID: 27405770]
[2]
WHO model list of essential medicines 20th List 2017.https://apps. who.int/iris/bitstream/handle/10665/273825/EMLc-6-eng.pdf?ua=1
[3]
Ku, L.C.; Zimmerman, K.; Benjamin, D.K.; Clark, R.H.; Hornik, C.P.; Smith, P.B. Best Pharmaceuticals for children act – pediatric trials network steering committee. Best pharmaceuticals for children act – pediatric trials network steering committee. Safety of enalapril in infants admitted to the neonatal intensive care unit. Pediatr. Cardiol., 2017, 38(1), 155-161.
[http://dx.doi.org/10.1007/s00246-016-1496-2] [PMID: 27826711]
[4]
Bajcetic, M.; de Wildt, S.N.; Dalinghaus, M. Breitkreutz. J.; Klingmann, I.; Lagler, F.B.; Keatley-Clarke, A.; Breur, J.Mpj.; Male, C.; Jovanovic, I.; Szatmári, A.; Ablonczy, L.; Burckhardt, B.B.; Cawello, W.; Kleine, K.; Obarcanin, E, Spatenkova, L.; Swoboda, V.; Van Der Meulend, M.; Wagner, P.; Walsh, J.; Läer S. Orodispersible minitablets of enalapril for use in children with heart failure (LENA): rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study. Contemp. Clin. Trials Commun., 2019, 15(100393), 1-8.
[5]
Moffett, B.S.; DiSanto, A.R.; Espinosa, O.; Hou, J.; Colabuono, P. Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets. Clin. Pharmacol. Drug Dev., 2014, 3(6), 493-498.
[http://dx.doi.org/10.1002/cpdd.129] [PMID: 27129124]
[6]
Strickley, R.G. Pediatric oral formulations: an updated review of commercially available pediatric oral formulations since 2007. J. Pharm. Sci., 2019, 108(4), 1335-1365.
[http://dx.doi.org/10.1016/j.xphs.2018.11.013] [PMID: 30447227]
[7]
Abay, F.B.; Ugurlu, T. Orally disintegrating tablets: a short review. J. Pharm. Drug. Devel., 2015, 3(3), 1-8.
[8]
Lopez, F.L.; Ernest, T.B.; Tuleu, C.; Gul, M.O. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert Opin. Drug Deliv., 2015, 12(11), 1727-1740.
[http://dx.doi.org/10.1517/17425247.2015.1060218] [PMID: 26165848]
[9]
Usman, S.; Ejaz, R.R.; Safdar, K.A. Formulation development and optimization of orally disintegrating tablets of montelukast sodium by design expert. Trop. J. Pharm. Res., 2018, 17(9), 1701-1709.
[http://dx.doi.org/10.4314/tjpr.v17i9.3]
[10]
Poller, B.; Strachan, C.; Broadbent, R.; Walker, G.F. A minitablet formulation made from electrospun nanofibers. Eur. J. Pharm. Biopharm., 2017, 114, 213-220.
[http://dx.doi.org/10.1016/j.ejpb.2017.01.022] [PMID: 28167295]
[11]
Stoltenberg, I.; Breitkreutz, J. Orally Disintegrating Mini-Tablets (ODMTs)--a novel solid oral dosage form for paediatric use. Eur. J. Pharm. Biopharm., 2011, 78(3), 462-469.
[http://dx.doi.org/10.1016/j.ejpb.2011.02.005] [PMID: 21324357]
[12]
Preis, M. Orally disintegrating films and mini-tablets-innovative dosage forms of choice for pediatric use. AAPS PharmSciTech, 2015, 16(2), 234-241.
[http://dx.doi.org/10.1208/s12249-015-0313-1] [PMID: 25739913]
[13]
Bowles, B.J.; Dziemidowicz, K.; Lopez, F.L.; Orlu, M.; Tuleu, C.; Edwards, A.J.; Ernest, T.B. Co-processed excipients for dispersible tablets-Part 1: manufacturability. AAPS PharmSciTech, 2018, 19(6), 2598-2609.
[http://dx.doi.org/10.1208/s12249-018-1090-4] [PMID: 29916193]
[14]
Atul, P.; Subrata, K.; Ganga, S. A review on co-processed excipients: a novel approach in formulation development. Int. J. Pharm. Innov., 2013, 3(5), 25-41.
[15]
Aulton, M.E. Farmacia la ciencia del diseño de las formas farmacéuticas, 2nd ed; Elsevier: Madrid, 2004, p. 696.
[16]
Yeleken, G.; Kotłowska, H.; Sznitowska, M.; Golenia, E.; Ustenova, G. Development of direct compressed loratadine minitablets. J. Pharm. Sci. & Res., 2017, 9(4), 401-406.
[17]
Pawar, H.; Varkhade, C.; Jadhav, P.; Mehra, K. Development and evaluation of orodispersible tablets using a natural polysaccharide isolated from Cassia tora seeds. Integr. Med. Res., 2014, 3(2), 91-98.
[http://dx.doi.org/10.1016/j.imr.2014.03.002] [PMID: 28664083]
[18]
The United States Pharmacopoeia-The National Formulary. USP, 41st NF 36th, The United States Pharmacopoeial Convention Inc: Rockville. 2019.
[19]
Shirsand, S.B.; Suresh, S.; Swamy, P.V.; Para, M.S.; Nagendra Kumar, D. Formulation design of fast disintegrating tablets using disintegrant blends. Indian J. Pharm. Sci., 2010, 72(1), 130-133.
[http://dx.doi.org/10.4103/0250-474X.62244] [PMID: 20582206]
[20]
Lima, D.M.; dos Santos, L.D.; Lima, E.M. Stability and in vitro release profile of enalapril maleate from different commercially available tablets: possible therapeutic implications. J. Pharm. Biomed. Anal., 2008, 47(4-5), 934-937.
[http://dx.doi.org/10.1016/j.jpba.2008.02.030] [PMID: 18472382]
[21]
WHO. Model formulary for children based on the second model list of essentials medicines for children 2009.. 2010.http://www.who.int/ selection_medicines/list/WMFc_2010.pdf
[22]
Pusapati, R.T.; Kumar, M.K.; Rapeti, S.S.; Murthy, T. Development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method. Int. J. Pharm. Investig., 2014, 4(2), 102-106.
[http://dx.doi.org/10.4103/2230-973X.133059] [PMID: 25006555]
[23]
Nagar, P.; Singh, K.; Chauhan, I.; Verma, M.; Yasir, M.; Khan, A.; Sharma, R.; Gupta, N. Orally disintegrating tablets: formulation, preparation techniques and evaluation. J. Appl. Pharm. Sci., 2011, 01(04), 35-45.
[24]
European Pharmacopoeia 5.0, 5th Ed, Directorate for the quality of medicines of the council of Europe: France 2004.
[25]
Gohel, M.; Jogani, P.D. An investigation of direct compression characteristics of co-processed lactose-starch using factorial design. Indian J. Pharm. Sci., 2003, 65(1), 31-38.
[26]
Villafuerte Robles, L. The excipients and their functionality in pharmaceutical solid products. Rev. Mex. Cienc. Farm., 2011, 42(1), 18-36.
[27]
Excipients, M.E.G.G.L.E. Technology. MEGGLE’s co-processed lactose grades for direct compression: StarLac®; Technical brochure Star-Lac; MEGGLE Group Wasserburg BG Excipients & Technology: Germany, 2019.

Rights & Permissions Print Cite
Article Metrics
23
2
© 2024 Bentham Science Publishers | Privacy Policy